ERBB2 and prostate carcinoma: Eloy and colleagues [65] were the first to report on CTX-modified liposomes for the selective delivery of DTX to prostate cancer after preparing TZM-functionalized liposomes encapsulating rapamycin alone [66] or with PTX [67] to treat HER2-positive breast cancer.